# A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)

> **NCT04107675** · PHASE2 · TERMINATED · sponsor: **Zambon SpA** · enrollment: 6 (actual)

## Conditions studied

- Bronchiolitis Obliterans Syndrome (BOS)
- GVHD, Chronic
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Liposomal Cyclosporine A
- **DRUG:** Liposomal Placebo

## Key facts

- **NCT ID:** NCT04107675
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-11
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-12-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to the low number of patients recruited and the slow enrollment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial ahead of time.
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107675, "A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04107675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*